A clinical study of effects of tamsulosin in ureteric stent related morbidity
DOI:
https://doi.org/10.18203/2349-2902.isj20230489Keywords:
DJ stent, Tamsulosin, Cystoureteroscopy, Ureteric stentAbstract
Background: Most of the Ureteric surgery involves DJ stent Insertion to prevent post operative ureter related morbidity of the patients. This study aims towards the role of tamsulosin in relieving DJ stent related symptoms.
Methods: Prospective study conducted between June 2018 to October 2020 in 58 patients randomised by random-number chart into two groups, group A (Non tamsulosin) group B (Tamsulosin). The international prostate symptom score (IPSS) questionnaire and quality of life (QoL) was assessed on admission as a baseline before patient underwent the surgery and reassessed when the patient came for stent removal.
Results: The mean age of patients in group A (non-tamsulosin) was 39.38 years with range of 20 to 60 years. The mean age of patients in group B (tamsulosin) was 38.55 with range of 20 to 68 years. In group A consisted of 16 men and 13 women whereas group B had 13 men and 16 women. On comparing non tamsulosin and tamsulosin group, patients in which stent is removed at or <28 post operative day, mean IPSS+QoL component of questionnaire score is 14.1 (SD 3.8) and 11.8 (SD 4.1) respectively. While on comparing non tamsulosin and tamsulosin group, patients in which stent removed after 28th post operative day, mean IPSS+QoL component of questionnaire score is 18.9 (SD 1.0) and 6.4 (SD 1.1) respectively.
Conclusions: Oral administration of tablet Tamsulosin 0.4 mg once a daily before sleep at night improves DJ stent related morbid symptoms.
References
Byrne RR, Auge BK, Kourambas J. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial. J Endourol. 2002;16:9-13.
Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59:511-9.
Chew BH, Knudsen BE, Nott L, Pautler SE, Razvi H, Amann J et al. Pilot Study of Ureteral Movement in Stented Patients: First Step in Understanding Dynamic Ureteral Anatomy to Improve Stent Discomfort. J Endourol. 2007;21:1069-75.
Andersson KE: Pharmacology of lower urinary tract smooth muscle and penile erectile tissues. Pharmacol Rev. 1993;45:253-308.
Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol. 1998;160:784-91.
Schulman CC, Lock TM, Buzelin JM. Longterm use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001;166:1358-63.
Hsiao SM, Lin HH, Kuo HC. International Prostate Symptom Score for assessing lower urinary tract dysfunction in women. Int Urogynecol J. 2013;24(2):263-7.
Cam K, Akman Y, Cicekci B, Senel F, Erol A. Mode of administration of international prostate symptom score in patients with lower urinary tract symptoms: physician vs self. Prostate Cancer Prostatic Dis. 2004;7(1):414.
Ata Ur Rehman R, Tahir MM, Seerwan M. Effect of tamsulosin on stent related symptoms; a prospective study. Professional Med J. 2016;23(1):114-8.
Karrupaiah P, Thiagarajan R, Ponnusamy P, Venkatachalam TP, Kumar K, Palanisamy G et al. A Study on the Effect of Tamsulosin in Ureteric Stent Related Morbidity. J Evolution Med Dental Sci. 2015;4(101):16662-6.
Navanimitkul N, Lojanapiwat B. Efficacy of Tamsulosin 0.4 mg/day in relieving Double J stent related symptoms:a randomized controlled study. J Int Med Res. 2010;143:6-41.
Young HH, McKay RW. Congenital valvular obstruction of the prostatic urethra. Surg Gynecol Obstet 1929;48:509-12.
